A detailed history of Raymond James Financial Services Advisors, Inc. transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Raymond James Financial Services Advisors, Inc. holds 7,787 shares of SRPT stock, worth $979,293. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,787
Previous 7,713 0.96%
Holding current value
$979,293
Previous $1.22 Million 20.2%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$124.33 - $156.75 $9,200 - $11,599
74 Added 0.96%
7,787 $972,000
Q2 2024

Jul 19, 2024

SELL
$113.33 - $163.85 $155,375 - $224,638
-1,371 Reduced 15.09%
7,713 $1.22 Million
Q1 2024

Apr 22, 2024

BUY
$93.7 - $141.53 $10,213 - $15,426
109 Added 1.21%
9,084 $1.18 Million
Q4 2023

Jan 16, 2024

SELL
$67.31 - $124.76 $65,559 - $121,516
-974 Reduced 9.79%
8,975 $865,000
Q3 2023

Oct 24, 2023

SELL
$102.5 - $123.59 $47,457 - $57,222
-463 Reduced 4.45%
9,949 $1.21 Million
Q2 2023

Jul 25, 2023

BUY
$106.4 - $157.19 $107,676 - $159,076
1,012 Added 10.77%
10,412 $1.19 Million
Q1 2023

Apr 14, 2023

SELL
$117.53 - $155.99 $736,560 - $977,589
-6,267 Reduced 40.0%
9,400 $1.3 Million
Q4 2022

Feb 08, 2023

BUY
$100.86 - $132.13 $407,070 - $533,276
4,036 Added 34.7%
15,667 $2.03 Million
Q3 2022

Oct 25, 2022

SELL
$75.71 - $119.24 $76,618 - $120,670
-1,012 Reduced 8.0%
11,631 $1.29 Million
Q2 2022

Aug 12, 2022

BUY
$62.69 - $88.44 $175,908 - $248,162
2,806 Added 28.52%
12,643 $948,000
Q1 2022

May 11, 2022

SELL
$63.15 - $90.42 $35,048 - $50,183
-555 Reduced 5.34%
9,837 $768,000
Q4 2021

Feb 08, 2022

SELL
$77.28 - $99.42 $937,560 - $1.21 Million
-12,132 Reduced 53.86%
10,392 $936,000
Q3 2021

Nov 02, 2021

SELL
$65.97 - $92.48 $571,696 - $801,431
-8,666 Reduced 27.78%
22,524 $2.08 Million
Q2 2021

Aug 11, 2021

BUY
$69.38 - $86.75 $39,685 - $49,621
572 Added 1.87%
31,190 $2.43 Million
Q1 2021

May 14, 2021

BUY
$72.25 - $168.95 $1.32 Million - $3.09 Million
18,301 Added 148.58%
30,618 $2.28 Million
Q4 2020

Feb 12, 2021

BUY
$125.56 - $178.74 $38,923 - $55,409
310 Added 2.58%
12,317 $2.1 Million
Q3 2020

Nov 04, 2020

BUY
$127.12 - $172.34 $110,594 - $149,935
870 Added 7.81%
12,007 $1.69 Million
Q2 2020

Jul 17, 2020

SELL
$93.0 - $171.7 $73,656 - $135,986
-792 Reduced 6.64%
11,137 $1.79 Million
Q1 2020

Apr 21, 2020

SELL
$82.38 - $131.64 $141,693 - $226,420
-1,720 Reduced 12.6%
11,929 $1.17 Million
Q4 2019

Feb 12, 2020

SELL
$76.53 - $135.58 $135,458 - $239,976
-1,770 Reduced 11.48%
13,649 $1.76 Million
Q3 2019

Nov 07, 2019

SELL
$72.81 - $156.91 $25,192 - $54,290
-346 Reduced 2.19%
15,419 $1.16 Million
Q2 2019

Aug 06, 2019

SELL
$112.21 - $151.95 $155,859 - $211,058
-1,389 Reduced 8.1%
15,765 $2.4 Million
Q1 2019

May 06, 2019

BUY
$106.67 - $151.68 $495,162 - $704,098
4,642 Added 37.1%
17,154 $2.05 Million
Q4 2018

Feb 11, 2019

BUY
$97.32 - $148.76 $82,916 - $126,743
852 Added 7.31%
12,512 $1.37 Million
Q3 2018

Nov 14, 2018

SELL
$115.31 - $161.51 $68,263 - $95,613
-592 Reduced 4.83%
11,660 $1.88 Million
Q2 2018

Jul 30, 2018

BUY
$71.74 - $153.69 $9,397 - $20,133
131 Added 1.08%
12,252 $1.62 Million
Q1 2018

Apr 16, 2018

SELL
$54.02 - $82.27 $352,102 - $536,235
-6,518 Reduced 34.97%
12,121 $898,000
Q4 2017

Feb 09, 2018

SELL
$47.64 - $56.75 $426,711 - $508,309
-8,957 Reduced 32.46%
18,639 $1.04 Million
Q3 2017

Oct 26, 2017

BUY
$35.73 - $47.15 $240,284 - $317,083
6,725 Added 32.22%
27,596 $1.25 Million
Q2 2017

Aug 15, 2017

BUY
N/A
20,871
20,871 $704,000

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $11B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.